GlassScriptPhysician profile
Tony Leung
NPI 1295991867
$2,290.95
in general payments reported to CMS, 2019-2025
15 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $139 · 2021: $134 · 2022: $430 · 2023: $646 · 2024: $545 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.66 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih Ab | $428.42 | 2022-2024 | Lofric, Lofric |
| Astellas Pharma US INC | $417.53 | 2019-2025 | Myrbetriq, Xtandi |
| Dentsply Ih INC. | $322.13 | 2019-2022 | |
| Convatec INC. | $258.89 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $173.34 | 2022-2023 | Xiaflex, Aveed, Edex |
| Abbvie INC. | $154.56 | 2022-2024 | |
| Myriad Genetic Laboratories, INC. | $129.04 | 2021-2024 | Myrisk, Prolaris |
| Ferring Pharmaceuticals INC. | $121.71 | 2024-2025 | Adstiladrin |
| Endo USA, INC. | $80.93 | 2024-2025 | Xiaflex |
| Janssen Biotech, INC. | $57.32 | 2019-2022 | |
| Edap Technomed INC | $40.00 | 2024 | |
| Coloplast Corp | $30.86 | 2025 | |
| Boston Scientific Corporation | $28.96 | 2023 | Lithovue |
| Allergan, INC. | $27.91 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $19.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.